(Q54070203)

English

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

B H Lenfers

1

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

T M Loeffler

2

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

C M Droege

3

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

T U Hausamen

4

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

publication date

1 October 1999

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

10

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

10

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

1251-1253

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended guidelines for the treatment of chemotherapy-induced diarrhea

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

A risk-benefit assessment of irinotecan in solid tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of diarrhea induced by tumors or cancer therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390308416

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008390308416

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10586346

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54070203&oldid=1584678296"